Itk Inhibitor Induces Th1 Skewing and Host Anti‐tumor Response Mediated by CD8+ TEMRA Cells in Refractory T Cell Lymphoma Patients

Ning Ding,Yun Xie,Richard A. Miller,S. Mahabhashyam,L. Hsu,Yanxia Guo,King C. Li,Tingting Du,Lan Mi,Ningjing Lin,Jingjing Cao,Dingyao Hu,D. Wang,Yunlei Li,Z. Li,Jun Zhu,Yuqin Song

DOI: https://doi.org/10.1002/hon.3164_193

IF: 4.85

2023-01-01

Hematological Oncology

Abstract:Interleukin 2 inducible T cell kinase (ITK) is involved in both T cell receptor (TCR) signaling and differentiation of helper T cells. ITK-/- mice have defects in Th2 differentiation resulting in skewing toward Th1 cells that secrete IFN-γ. CPI-818 is a selective covalent inhibitor of ITK (Kd 2.5 nM). Its activity was assessed in murine T cell lymphoma EL4 model and demonstrated anti-tumor activity by increasing infiltration of normal CD8+ T cells in the tumors. In vivo CD8 and CD4 depletion reduced CPI-818 anti-tumor activity, indicating that tumor microenvironment infiltrating normal T cells are essential for the anti-tumor activity. Similar results were observed in murine syngeneic B cell lymphoma A20 and colon cancer CT26 models supporting a role for host anti-tumor immunity. CPI-818 is now being evaluated in an ongoing Phase 1 trial in refractory T cell lymphoma (TCL). Fifty-four patients (pts) with TCL were enrolled in a dose escalation trial receiving doses of 100–600 mg bid of CPI-818 until progression. Pts had a median age of 62 years and a median of four prior therapies. In vitro studies and clinical response data indicated that the optimum dose was 200 mg bid; a dose associated with effects on T cell differentiation based on demonstration of Th1 skewing in vitro and in vivo. In the 200 mg cohort (N = 20 enrolled with 13 evaluable) there have been 1 CR 25 months (PTCL), 1 nodal CR 21 months (CTCL), 1 PR 12+ mo (PTCL) and 1 PR 7 months (ALCL). Ten pts remain on therapy. 1 PR also was seen in a pt receiving 600 mg bid (PTCL). Drug related Grade 3/4 AEs reported in 4/0 pts. Single cell RNA-seq analyses using peripheral blood and tumor tissue samples was performed and revealed that treatment: reduced malignant T cell proliferation by down-regulating cell cycle and DNA replication pathways; increased PRF1+, IFNG+, and GZMB+ CD8 subpopulations; induced clonal expansion of normal CD8 T cells; inhibited Treg cell activity by decreasing the expression of FOXP3 and IL2RA. Flow cytometry of peripheral blood from 3 PR patients revealed higher levels of Th1 cells (CD3+/CD4+/CD8-/CD183+/CD196-) and CD8+ terminally differentiated T effector memory cells (TEMRA CD3+/CD4-/CD8+/CD197-/CD45RA+) compared to baseline. Our findings suggest that selective ITK blockade has an immunomodulatory effect, which could represent a potentially novel immunotherapy approach for the treatment of T cell lymphomas and other tumors. The research was funded by: The research was funded by Corvus Pharmaceuticals and Angel Pharmaceuticals. Keywords: Immunotherapy, Molecular Targeted Therapies, Targeting the Tumor Microenvironment Conflicts of interests pertinent to the abstract. R. Miller Employment or leadership position: Corvus Pharmaceuticals, Angel Pharmaceuticals Stock ownership: Corvus Pharmaceuticals S. Mahabhashyam Employment or leadership position: Corvus Pharmaceuticals Stock ownership: Corvus Pharmaceuticals L. Hsu Employment or leadership position: Corvus Pharmaceuticals